A single center, randomized, open-label, crossover, single oral dose study to assess the bioequivalence of LAF237 [Vildagliptin] tablet manufactured by Beijing Novartis Pharma Ltd. to imported LAF237 tablet in Chinese healthy subjects
Latest Information Update: 24 Apr 2013
Price :
$35 *
At a glance
- Drugs Vildagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novartis
- 21 Jun 2007 Status change from in progress to completed
- 11 Jan 2007 New trial record.